The validation of ADAMDEC1 in clinical SF samples demonstrated its robustness in identifying RA lesions, even in patients’ post-joint replacement, underscoring its potential as a diagnostic and prognostic biomarker. This evidence concerns the gene ADAMDEC1 and rheumatoid arthritis.